Ionis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.35), $0.23 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $133 million versus the consensus estimate of $161.13 million.

• On track to achieve 2020 financial guidance
• "We are reaffirming our 2020 financial guidance, including ending 2020 meaningfully profitable. We expect our results to be driven by continued significant commercial revenue and R&D revenue from numerous programs," said Elizabeth L. Hougen, chief financial officer of Ionis. "We remain well-capitalized, with a strong balance sheet and $2.4 billion in cash and investments. Enabled by our financial strength, we have the resources to execute on our near- and longer-term strategic priorities, even in the challenging COVID-19 pandemic environment."

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.